<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85008618934</prism:url><dc:identifier>SCOPUS_ID:85008618934</dc:identifier><eid>2-s2.0-85008618934</eid><pubmed-id>28089159</pubmed-id><pii>S1525730416303758</pii><prism:doi>10.1016/j.cllc.2016.11.021</prism:doi><dc:title>Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>3</citedby-count><prism:publicationName>Clinical Lung Cancer</prism:publicationName><dc:publisher> Elsevier Inc. usjcs@elsevier.com </dc:publisher><source-id>29265</source-id><prism:issn>19380690 15257304</prism:issn><prism:volume>18</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:startingPage>e187</prism:startingPage><prism:endingPage>e196</prism:endingPage><prism:pageRange>e187-e196</prism:pageRange><prism:coverDate>2017-05-01</prism:coverDate><openaccess/><openaccessFlag/><dc:creator><author seq="1" auid="56245036500"><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.T.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnšek</ce:given-name><preferred-name><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnšek</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56245036500</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"> <publishercopyright>© 2016 Elsevier Inc.</publishercopyright> <ce:para>We evaluated the use of immunohistochemistry (IHC) for detection of epidermal growth factor receptor (EGFR) mutations in non&amp;#x2013;small-cell lung cancer on a cohort of 79 EGFR-mutated Whites. IHC demonstrated high accuracy for detection of common EGFR mutations as well as for predicting response to EGFR tyrosine kinase inhibitors as compared with standard polymerase chain reaction&amp;#x2013;based methodology. Cost-effective use of upfront IHC depends mainly on the population EGFR mutation positivity probability. Introduction The sensitivity and specificity of immunohistochemistry (IHC) was compared with the standard polymerase chain reaction (PCR)-based method for detecting common activating epidermal growth factor receptor (EGFR) mutations in non&amp;#x2013;small-cell lung cancer (NSCLC). Additionally, we evaluated predictive value of IHC EGFR mutation&amp;#x2013;positive status for EGFR tyrosine kinase inhibitor (TKI) treatment outcome and estimated cost-effectiveness for the upfront IHC testing. Methods The trial included 79 consecutive EGFR mutation&amp;#x2013;positive and 29 EGFR mutation&amp;#x2013;negative NSCLC cases diagnosed with reflex PCR-based testing. Two mutation-specific antibodies against the most common exon 19 deletion, namely E746-A750del (clone SP111) and L858R mutation (clone SP125) were tested by using automated immunostainer. Sixty of 79 EGFR mutation&amp;#x2013;positive cases were treated with EGFR TKIs for advanced disease and included in treatment outcome analysis. A decision tree was used for the cost-effectiveness analysis. Results The overall sensitivity and specificity of the IHC-based method compared with the PCR-based method were 84.8% (95% confidence interval [CI] 74.6&amp;#x2013;91.6) and 100% (95% CI 85.4&amp;#x2013;100), respectively. The median progression-free survival (PFS) and overall survival (OS) of patients with IHC-positive EGFR mutation status were highly comparable to the total cohort (PFS: 14.3 vs. 14.0 months; OS: 34.4 vs. 34.4 months). The PCR and IHC cost ratio needs to be approximately 8-to-1 and 4-to-1 in White and Asian populations, respectively, to economically justify upfront use of IHC. Conclusion The trial confirmed an excellent specificity with fairly good sensitivity of IHC with mutation-specific antibodies for common EGFR mutations and the accuracy of IHC testing for predicting response to EGFR TKIs. The use of upfront IHC depends mainly on the population EGFR mutation positivity probability.</ce:para> </abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85008618934" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85008618934&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85008618934&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"><affilname>University of Ljubljana Faculty of Medicine</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"><affilname>Onkološki inštitut Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="56245036500"><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.T.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnšek</ce:given-name><preferred-name><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnšek</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56245036500</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="2" auid="7003295818"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7003295818</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="3" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="4" auid="23976089500"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23976089500</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="5" auid="36574425600"><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanič</ce:surname><ce:given-name>Karmen</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Stanič K.</ce:indexed-name><ce:surname>Stanič</ce:surname><ce:given-name>Karmen</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36574425600</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="6" auid="56031379200"><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaž</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaž</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56031379200</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="7" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Cost-effectiveness</author-keyword><author-keyword>Epidermal growth factor receptor mutation</author-keyword><author-keyword>Mutation-specific antibodies</author-keyword><author-keyword>NSCLC</author-keyword><author-keyword>Survival</author-keyword></authkeywords><idxterms><mainterm weight="b" candidate="n">Adult</mainterm><mainterm weight="b" candidate="n">Aged</mainterm><mainterm weight="b" candidate="n">Aged, 80 and over</mainterm><mainterm weight="b" candidate="n">Carcinoma, Non-Small-Cell Lung</mainterm><mainterm weight="b" candidate="n">Cohort Studies</mainterm><mainterm weight="b" candidate="n">Cost-Benefit Analysis</mainterm><mainterm weight="b" candidate="n">Feasibility Studies</mainterm><mainterm weight="b" candidate="n">Humans</mainterm><mainterm weight="b" candidate="n">Immunohistochemistry</mainterm><mainterm weight="b" candidate="n">Lung</mainterm><mainterm weight="b" candidate="n">Lung Neoplasms</mainterm><mainterm weight="b" candidate="n">Middle Aged</mainterm><mainterm weight="b" candidate="n">Mutation</mainterm><mainterm weight="b" candidate="n">Neoplasm Staging</mainterm><mainterm weight="b" candidate="n">Polymerase Chain Reaction</mainterm><mainterm weight="b" candidate="n">Receptor, Epidermal Growth Factor</mainterm><mainterm weight="b" candidate="n">Sensitivity and Specificity</mainterm><mainterm weight="b" candidate="n">Survival Analysis</mainterm></idxterms><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="2740" abbrev="MEDI">Pulmonary and Respiratory Medicine</subject-area><subject-area code="1306" abbrev="BIOC">Cancer Research</subject-area></subject-areas><item xmlns=""><ait:process-info><ait:date-delivered day="15" month="03" timestamp="2018-03-15T02:20:35.000035-04:00" year="2018"/><ait:date-sort day="01" month="05" year="2017"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2017 Elsevier B.V., All rights reserved.</copyright><itemidlist> <ce:pii>S1525730416303758</ce:pii> <ce:doi>10.1016/j.cllc.2016.11.021</ce:doi> <itemid idtype="PUI">614020379</itemid> <itemid idtype="CAR-ID">659955233</itemid> <itemid idtype="EMBASE">20170031037</itemid> <itemid idtype="NURSNG">2017014630</itemid> <itemid idtype="REAXYSCAR">20170072084</itemid> <itemid idtype="SCP">85008618934</itemid> <itemid idtype="SGR">85008618934</itemid> <itemid idtype="PUIsecondary">621193436</itemid> <itemid idtype="MEDL">28089159</itemid> </itemidlist><history> <date-created day="13" month="10" timestamp="BST 14:59:21" year="2017"/> </history><dbcollection>EMBASE</dbcollection><dbcollection>NURSNG</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>Scopusbase</dbcollection><dbcollection>MEDL</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords> <author-keyword>Cost-effectiveness</author-keyword> <author-keyword>Epidermal growth factor receptor mutation</author-keyword> <author-keyword>Mutation-specific antibodies</author-keyword> <author-keyword>NSCLC</author-keyword> <author-keyword>Survival</author-keyword> </author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer</titletext></citation-title><author-group><author auid="56245036500" seq="1" type="auth"><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.T.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnšek</ce:given-name><preferred-name> <ce:initials>N.T.</ce:initials> <ce:indexed-name>Hitij N.</ce:indexed-name> <ce:surname>Hitij</ce:surname> <ce:given-name>Nina Turnšek</ce:given-name> </preferred-name></author><author auid="7003295818" seq="2" type="auth"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name> <ce:initials>I.</ce:initials> <ce:indexed-name>Kern I.</ce:indexed-name> <ce:surname>Kern</ce:surname> <ce:given-name>Izidor</ce:given-name> </preferred-name></author><author auid="23976089500" seq="4" type="auth"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name><preferred-name> <ce:initials>L.</ce:initials> <ce:indexed-name>Knez L.</ce:indexed-name> <ce:surname>Knez</ce:surname> <ce:given-name>Lea</ce:given-name> </preferred-name></author><author auid="7004393140" orcid="0000-0002-4417-7161" seq="7" type="auth"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name> <ce:initials>T.</ce:initials> <ce:indexed-name>Cufer T.</ce:indexed-name> <ce:surname>Cufer</ce:surname> <ce:given-name>Tanja</ce:given-name> </preferred-name></author><affiliation afid="60078312" country="svn"><organization>University Clinic Golnik</organization><city>Golnik</city><affiliation-id afid="60078312"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="3" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name> <ce:initials>A.</ce:initials> <ce:indexed-name>Sadikov A.</ce:indexed-name> <ce:surname>Sadikov</ce:surname> <ce:given-name>Aleksander</ce:given-name> </preferred-name></author><affiliation afid="60031106" country="svn"><organization>Faculty of Computer and Information Science</organization><organization>University of Ljubljana</organization><city>Ljubljana</city><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="36574425600" seq="5" type="auth"><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanič</ce:surname><ce:given-name>Karmen</ce:given-name><preferred-name> <ce:initials>K.</ce:initials> <ce:indexed-name>Stanič K.</ce:indexed-name> <ce:surname>Stanič</ce:surname> <ce:given-name>Karmen</ce:given-name> </preferred-name></author><author auid="56031379200" seq="6" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaž</ce:given-name><preferred-name> <ce:initials>M.</ce:initials> <ce:indexed-name>Zwitter M.</ce:indexed-name> <ce:surname>Zwitter</ce:surname> <ce:given-name>Matjaž</ce:given-name> </preferred-name></author><affiliation afid="60000966" country="svn"><organization>Institute of Oncology</organization><city>Ljubljana</city><affiliation-id afid="60000966"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="7004393140" orcid="0000-0002-4417-7161" seq="7" type="auth"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name> <ce:initials>T.</ce:initials> <ce:indexed-name>Cufer T.</ce:indexed-name> <ce:surname>Cufer</ce:surname> <ce:given-name>Tanja</ce:given-name> </preferred-name></author><affiliation afid="60021802" country="svn"><organization>Faculty of Medicine</organization><organization>University of Ljubljana</organization><city>Ljubljana</city><affiliation-id afid="60021802"/><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><correspondence><person> <ce:initials>N.T.</ce:initials> <ce:indexed-name>Hitij N.T.</ce:indexed-name> <ce:surname>Hitij</ce:surname> <ce:given-name>Nina Turnšek</ce:given-name> </person><affiliation country="svn"><organization>University Clinic Golnik</organization><address-part>Golnik 36</address-part><city>Golnik</city><postal-code>4204</postal-code><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"> <publishercopyright>© 2016 Elsevier Inc.</publishercopyright> <ce:para>We evaluated the use of immunohistochemistry (IHC) for detection of epidermal growth factor receptor (EGFR) mutations in non&amp;#x2013;small-cell lung cancer on a cohort of 79 EGFR-mutated Whites. IHC demonstrated high accuracy for detection of common EGFR mutations as well as for predicting response to EGFR tyrosine kinase inhibitors as compared with standard polymerase chain reaction&amp;#x2013;based methodology. Cost-effective use of upfront IHC depends mainly on the population EGFR mutation positivity probability. Introduction The sensitivity and specificity of immunohistochemistry (IHC) was compared with the standard polymerase chain reaction (PCR)-based method for detecting common activating epidermal growth factor receptor (EGFR) mutations in non&amp;#x2013;small-cell lung cancer (NSCLC). Additionally, we evaluated predictive value of IHC EGFR mutation&amp;#x2013;positive status for EGFR tyrosine kinase inhibitor (TKI) treatment outcome and estimated cost-effectiveness for the upfront IHC testing. Methods The trial included 79 consecutive EGFR mutation&amp;#x2013;positive and 29 EGFR mutation&amp;#x2013;negative NSCLC cases diagnosed with reflex PCR-based testing. Two mutation-specific antibodies against the most common exon 19 deletion, namely E746-A750del (clone SP111) and L858R mutation (clone SP125) were tested by using automated immunostainer. Sixty of 79 EGFR mutation&amp;#x2013;positive cases were treated with EGFR TKIs for advanced disease and included in treatment outcome analysis. A decision tree was used for the cost-effectiveness analysis. Results The overall sensitivity and specificity of the IHC-based method compared with the PCR-based method were 84.8% (95% confidence interval [CI] 74.6&amp;#x2013;91.6) and 100% (95% CI 85.4&amp;#x2013;100), respectively. The median progression-free survival (PFS) and overall survival (OS) of patients with IHC-positive EGFR mutation status were highly comparable to the total cohort (PFS: 14.3 vs. 14.0 months; OS: 34.4 vs. 34.4 months). The PCR and IHC cost ratio needs to be approximately 8-to-1 and 4-to-1 in White and Asian populations, respectively, to economically justify upfront use of IHC. Conclusion The trial confirmed an excellent specificity with fairly good sensitivity of IHC with mutation-specific antibodies for common EGFR mutations and the accuracy of IHC testing for predicting response to EGFR TKIs. The use of upfront IHC depends mainly on the population EGFR mutation positivity probability.</ce:para> </abstract></abstracts><source country="usa" srcid="29265" type="j"><sourcetitle>Clinical Lung Cancer</sourcetitle><sourcetitle-abbrev>Clin. Lung Cancer</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Clinical Lung Cancer</translated-sourcetitle><issn type="electronic">19380690</issn><issn type="print">15257304</issn><codencode>CLCLC</codencode><volisspag> <voliss issue="3" volume="18"/> <pagerange first="e187" last="e196"/> </volisspag><publicationyear first="2017"/><publicationdate> <year>2017</year> <month>05</month> <day>01</day> <date-text>May 2017</date-text> </publicationdate><website> <ce:e-address type="email">http://www.journals.elsevier.com/clinical-lung-cancer/</ce:e-address> </website><publisher> <publishername>Elsevier Inc.</publishername> <ce:e-address type="email">usjcs@elsevier.com</ce:e-address> </publisher></source><enhancement><classificationgroup><classifications type="EMCLASS"> <classification> <classification-code>15</classification-code> <classification-description>Chest Diseases, Thoracic Surgery and Tuberculosis</classification-description> </classification> <classification> <classification-code>16</classification-code> <classification-description>Cancer</classification-description> </classification> <classification> <classification-code>22</classification-code> <classification-description>Human Genetics</classification-description> </classification> <classification> <classification-code>29</classification-code> <classification-description>Clinical and Experimental Biochemistry</classification-description> </classification> <classification> <classification-code>36</classification-code> <classification-description>Health Policy, Economics and Management</classification-description> </classification> <classification> <classification-code>5</classification-code> <classification-description>General Pathology and Pathological Anatomy</classification-description> </classification> </classifications><classifications type="ASJC"> <classification>2730</classification> <classification>2740</classification> <classification>1306</classification> </classifications><classifications type="SUBJABBR"><classification>MEDI</classification><classification>BIOC</classification></classifications></classificationgroup><chemicalgroup> <chemicals source="esbd"> <chemical> <chemical-name>epidermal growth factor receptor</chemical-name> <cas-registry-number>79079-06-4</cas-registry-number> </chemical> </chemicals> <chemicals source="nlm"> <chemical> <chemical-name>EGFR protein, human</chemical-name> </chemical> <chemical> <chemical-name>Receptor, Epidermal Growth Factor</chemical-name> </chemical> </chemicals> </chemicalgroup></enhancement></head><tail><bibliography refcount="45"> <reference id="1"> <ref-info> <ref-title> <ref-titletext>Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib1</itemid> <itemid idtype="SGR">0037050352</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.H.</ce:initials> <ce:indexed-name>Schiller J.H.</ce:indexed-name> <ce:surname>Schiller</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Harrington D.</ce:indexed-name> <ce:surname>Harrington</ce:surname> </author> <author seq="3"> <ce:initials>C.P.</ce:initials> <ce:indexed-name>Belani C.P.</ce:indexed-name> <ce:surname>Belani</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>N Engl J Med</ref-sourcetitle> <ref-publicationyear first="2002"/> <ref-volisspag> <voliss volume="346"/> <pagerange first="92" last="98"/> </ref-volisspag> </ref-info> <ref-fulltext>1 Schiller, J.H., Harrington, D., Belani, C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002), 92–98.</ref-fulltext> </reference> <reference id="2"> <ref-info> <ref-title> <ref-titletext>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib2</itemid> <itemid idtype="SGR">2342471392</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.J.</ce:initials> <ce:indexed-name>Lynch T.J.</ce:indexed-name> <ce:surname>Lynch</ce:surname> </author> <author seq="2"> <ce:initials>D.W.</ce:initials> <ce:indexed-name>Bell D.W.</ce:indexed-name> <ce:surname>Bell</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Sordella R.</ce:indexed-name> <ce:surname>Sordella</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>N Engl J Med</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="350"/> <pagerange first="2129" last="2139"/> </ref-volisspag> </ref-info> <ref-fulltext>2 Lynch, T.J., Bell, D.W., Sordella, R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004), 2129–2139.</ref-fulltext> </reference> <reference id="3"> <ref-info> <ref-title> <ref-titletext>EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib3</itemid> <itemid idtype="SGR">4444344330</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Pao W.</ce:indexed-name> <ce:surname>Pao</ce:surname> </author> <author seq="2"> <ce:initials>V.</ce:initials> <ce:indexed-name>Miller V.</ce:indexed-name> <ce:surname>Miller</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Zakowski M.</ce:indexed-name> <ce:surname>Zakowski</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Proc Natl Acad Sci U S A</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="101"/> <pagerange first="13306" last="13311"/> </ref-volisspag> </ref-info> <ref-fulltext>3 Pao, W., Miller, V., Zakowski, M., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004), 13306–13311.</ref-fulltext> </reference> <reference id="4"> <ref-info> <ref-title> <ref-titletext>Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib4</itemid> <itemid idtype="SGR">84898748420</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.K.</ce:initials> <ce:indexed-name>Lee J.K.</ce:indexed-name> <ce:surname>Lee</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Hahn S.</ce:indexed-name> <ce:surname>Hahn</ce:surname> </author> <author seq="3"> <ce:initials>D.W.</ce:initials> <ce:indexed-name>Kim D.W.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>JAMA</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="311"/> <pagerange first="1430" last="1437"/> </ref-volisspag> </ref-info> <ref-fulltext>4 Lee, J.K., Hahn, S., Kim, D.W., et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 311 (2014), 1430–1437.</ref-fulltext> </reference> <reference id="5"> <ref-info> <ref-title> <ref-titletext>2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib5</itemid> <itemid idtype="SGR">84905195418</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>B.</ce:initials> <ce:indexed-name>Besse B.</ce:indexed-name> <ce:surname>Besse</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Adjei A.</ce:indexed-name> <ce:surname>Adjei</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Baas P.</ce:indexed-name> <ce:surname>Baas</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Ann Oncol</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="25"/> <pagerange first="1475" last="1484"/> </ref-volisspag> </ref-info> <ref-fulltext>5 Besse, B., Adjei, A., Baas, P., et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 25 (2014), 1475–1484.</ref-fulltext> </reference> <reference id="6"> <ref-info> <ref-title> <ref-titletext>Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib6</itemid> <itemid idtype="SGR">84906860520</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>K.M.</ce:initials> <ce:indexed-name>Kerr K.M.</ce:indexed-name> <ce:surname>Kerr</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Bubendorf L.</ce:indexed-name> <ce:surname>Bubendorf</ce:surname> </author> <author seq="3"> <ce:initials>M.J.</ce:initials> <ce:indexed-name>Edelman M.J.</ce:indexed-name> <ce:surname>Edelman</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Ann Oncol</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="25"/> <pagerange first="1681" last="1690"/> </ref-volisspag> </ref-info> <ref-fulltext>6 Kerr, K.M., Bubendorf, L., Edelman, M.J., et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 25 (2014), 1681–1690.</ref-fulltext> </reference> <reference id="7"> <ref-info> <ref-title> <ref-titletext>Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib7</itemid> <itemid idtype="SGR">84880917028</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.I.</ce:initials> <ce:indexed-name>Lindeman N.I.</ce:indexed-name> <ce:surname>Lindeman</ce:surname> </author> <author seq="2"> <ce:initials>P.T.</ce:initials> <ce:indexed-name>Cagle P.T.</ce:indexed-name> <ce:surname>Cagle</ce:surname> </author> <author seq="3"> <ce:initials>M.B.</ce:initials> <ce:indexed-name>Beasley M.B.</ce:indexed-name> <ce:surname>Beasley</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Thorac Oncol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="8"/> <pagerange first="823" last="859"/> </ref-volisspag> </ref-info> <ref-fulltext>7 Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8 (2013), 823–859.</ref-fulltext> </reference> <reference id="8"> <ref-info> <ref-title> <ref-titletext>Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib8</itemid> <itemid idtype="SGR">79957916527</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.Y.</ce:initials> <ce:indexed-name>Wu J.Y.</ce:indexed-name> <ce:surname>Wu</ce:surname> </author> <author seq="2"> <ce:initials>C.J.</ce:initials> <ce:indexed-name>Yu C.J.</ce:indexed-name> <ce:surname>Yu</ce:surname> </author> <author seq="3"> <ce:initials>Y.C.</ce:initials> <ce:indexed-name>Chang Y.C.</ce:indexed-name> <ce:surname>Chang</ce:surname> </author> <author seq="4"> <ce:initials>C.H.</ce:initials> <ce:indexed-name>Yang C.H.</ce:indexed-name> <ce:surname>Yang</ce:surname> </author> <author seq="5"> <ce:initials>J.Y.</ce:initials> <ce:indexed-name>Shih J.Y.</ce:indexed-name> <ce:surname>Shih</ce:surname> </author> <author seq="6"> <ce:initials>P.C.</ce:initials> <ce:indexed-name>Yang P.C.</ce:indexed-name> <ce:surname>Yang</ce:surname> </author> </ref-authors> <ref-sourcetitle>Clin Cancer Res</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="17"/> <pagerange first="3812" last="3821"/> </ref-volisspag> </ref-info> <ref-fulltext>8 Wu, J.Y., Yu, C.J., Chang, Y.C., Yang, C.H., Shih, J.Y., Yang, P.C., Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17 (2011), 3812–3821.</ref-fulltext> </reference> <reference id="9"> <ref-info> <ref-title> <ref-titletext>Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib9</itemid> <itemid idtype="SGR">77649140830</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Brevet M.</ce:indexed-name> <ce:surname>Brevet</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Arcila M.</ce:indexed-name> <ce:surname>Arcila</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Ladanyi M.</ce:indexed-name> <ce:surname>Ladanyi</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Mol Diagn</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="12"/> <pagerange first="169" last="176"/> </ref-volisspag> </ref-info> <ref-fulltext>9 Brevet, M., Arcila, M., Ladanyi, M., Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12 (2010), 169–176.</ref-fulltext> </reference> <reference id="10"> <ref-info> <ref-title> <ref-titletext>COSMIC: exploring the world's knowledge of somatic mutations in human cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib10</itemid> <itemid idtype="SGR">84946040120</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.A.</ce:initials> <ce:indexed-name>Forbes S.A.</ce:indexed-name> <ce:surname>Forbes</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Beare D.</ce:indexed-name> <ce:surname>Beare</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Gunasekaran P.</ce:indexed-name> <ce:surname>Gunasekaran</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Nucleic Acids Res</ref-sourcetitle> <ref-publicationyear first="2015"/> <ref-volisspag> <voliss volume="43"/> <pagerange first="D805" last="D811"/> </ref-volisspag> </ref-info> <ref-fulltext>10 Forbes, S.A., Beare, D., Gunasekaran, P., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43 (2015), D805–D811.</ref-fulltext> </reference> <reference id="11"> <ref-info> <ref-title> <ref-titletext>Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib11</itemid> <itemid idtype="SGR">84911866971</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.B.</ce:initials> <ce:indexed-name>Leighl N.B.</ce:indexed-name> <ce:surname>Leighl</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>Rekhtman N.</ce:indexed-name> <ce:surname>Rekhtman</ce:surname> </author> <author seq="3"> <ce:initials>W.A.</ce:initials> <ce:indexed-name>Biermann W.A.</ce:indexed-name> <ce:surname>Biermann</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Oncol</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="32"/> <pagerange first="3673" last="3679"/> </ref-volisspag> </ref-info> <ref-fulltext>11 Leighl, N.B., Rekhtman, N., Biermann, W.A., et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 32 (2014), 3673–3679.</ref-fulltext> </reference> <reference id="12"> <ref-info> <ref-title> <ref-titletext>EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib12</itemid> <itemid idtype="SGR">84874606355</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Ellison G.</ce:indexed-name> <ce:surname>Ellison</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Zhu G.</ce:indexed-name> <ce:surname>Zhu</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Moulis A.</ce:indexed-name> <ce:surname>Moulis</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Dearden S.</ce:indexed-name> <ce:surname>Dearden</ce:surname> </author> <author seq="5"> <ce:initials>G.</ce:initials> <ce:indexed-name>Speake G.</ce:indexed-name> <ce:surname>Speake</ce:surname> </author> <author seq="6"> <ce:initials>R.</ce:initials> <ce:indexed-name>McCormack R.</ce:indexed-name> <ce:surname>McCormack</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Pathol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="66"/> <pagerange first="79" last="89"/> </ref-volisspag> </ref-info> <ref-fulltext>12 Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., McCormack, R., EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66 (2013), 79–89.</ref-fulltext> </reference> <reference id="13"> <ref-info> <ref-title> <ref-titletext>Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib13</itemid> <itemid idtype="SGR">65649128973</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Yu J.</ce:indexed-name> <ce:surname>Yu</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Kane S.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Wu J.</ce:indexed-name> <ce:surname>Wu</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Clin Cancer Res</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="15"/> <pagerange first="3023" last="3028"/> </ref-volisspag> </ref-info> <ref-fulltext>13 Yu, J., Kane, S., Wu, J., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15 (2009), 3023–3028.</ref-fulltext> </reference> <reference id="14"> <ref-info> <ref-title> <ref-titletext>Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib14</itemid> <itemid idtype="SGR">84898058460</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Allo G.</ce:indexed-name> <ce:surname>Allo</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Bandarchi B.</ce:indexed-name> <ce:surname>Bandarchi</ce:surname> </author> <author seq="3"> <ce:initials>N.</ce:initials> <ce:indexed-name>Yanagawa N.</ce:indexed-name> <ce:surname>Yanagawa</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Histopathology</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="64"/> <pagerange first="826" last="839"/> </ref-volisspag> </ref-info> <ref-fulltext>14 Allo, G., Bandarchi, B., Yanagawa, N., et al. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma. Histopathology 64 (2014), 826–839.</ref-fulltext> </reference> <reference id="15"> <ref-info> <ref-title> <ref-titletext>EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib15</itemid> <itemid idtype="SGR">84862854126</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Ambrosini-Spaltro A.</ce:indexed-name> <ce:surname>Ambrosini-Spaltro</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>Campanini N.</ce:indexed-name> <ce:surname>Campanini</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Bortesi B.</ce:indexed-name> <ce:surname>Bortesi</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Appl Immunohistochem Mol Morphol</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="20"/> <pagerange first="356" last="362"/> </ref-volisspag> </ref-info> <ref-fulltext>15 Ambrosini-Spaltro, A., Campanini, N., Bortesi, B., et al. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing. Appl Immunohistochem Mol Morphol 20 (2012), 356–362.</ref-fulltext> </reference> <reference id="16"> <ref-info> <ref-title> <ref-titletext>High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib16</itemid> <itemid idtype="SGR">84927178547</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.L.</ce:initials> <ce:indexed-name>Bondgaard A.L.</ce:indexed-name> <ce:surname>Bondgaard</ce:surname> </author> <author seq="2"> <ce:initials>E.</ce:initials> <ce:indexed-name>Hogdall E.</ce:indexed-name> <ce:surname>Høgdall</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Mellemgaard A.</ce:indexed-name> <ce:surname>Mellemgaard</ce:surname> </author> <author seq="4"> <ce:initials>B.G.</ce:initials> <ce:indexed-name>Skov B.G.</ce:indexed-name> <ce:surname>Skov</ce:surname> </author> </ref-authors> <ref-sourcetitle>Mod Pathol</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="27"/> <pagerange first="1590" last="1598"/> </ref-volisspag> </ref-info> <ref-fulltext>16 Bondgaard, A.L., Høgdall, E., Mellemgaard, A., Skov, B.G., High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. Mod Pathol 27 (2014), 1590–1598.</ref-fulltext> </reference> <reference id="17"> <ref-info> <ref-title> <ref-titletext>EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib17</itemid> <itemid idtype="SGR">84882831490</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.A.</ce:initials> <ce:indexed-name>Cooper W.A.</ce:indexed-name> <ce:surname>Cooper</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Yu B.</ce:indexed-name> <ce:surname>Yu</ce:surname> </author> <author seq="3"> <ce:initials>P.Y.</ce:initials> <ce:indexed-name>Yip P.Y.</ce:indexed-name> <ce:surname>Yip</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Pathol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="66"/> <pagerange first="744" last="748"/> </ref-volisspag> </ref-info> <ref-fulltext>17 Cooper, W.A., Yu, B., Yip, P.Y., et al. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. J Clin Pathol 66 (2013), 744–748.</ref-fulltext> </reference> <reference id="18"> <ref-info> <ref-title> <ref-titletext>Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib18</itemid> <itemid idtype="SGR">84880325532</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>X.</ce:initials> <ce:indexed-name>Fan X.</ce:indexed-name> <ce:surname>Fan</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Liu B.</ce:indexed-name> <ce:surname>Liu</ce:surname> </author> <author seq="3"> <ce:initials>H.</ce:initials> <ce:indexed-name>Xu H.</ce:indexed-name> <ce:surname>Xu</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Hum Pathol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="44"/> <pagerange first="1499" last="1507"/> </ref-volisspag> </ref-info> <ref-fulltext>18 Fan, X., Liu, B., Xu, H., et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum Pathol 44 (2013), 1499–1507.</ref-fulltext> </reference> <reference id="19"> <ref-info> <ref-title> <ref-titletext>Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib19</itemid> <itemid idtype="SGR">84863781238</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Hasanovic A.</ce:indexed-name> <ce:surname>Hasanovic</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Ang D.</ce:indexed-name> <ce:surname>Ang</ce:surname> </author> <author seq="3"> <ce:initials>A.L.</ce:initials> <ce:indexed-name>Moreira A.L.</ce:indexed-name> <ce:surname>Moreira</ce:surname> </author> <author seq="4"> <ce:initials>M.F.</ce:initials> <ce:indexed-name>Zakowski M.F.</ce:indexed-name> <ce:surname>Zakowski</ce:surname> </author> </ref-authors> <ref-sourcetitle>Lung Cancer</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="77"/> <pagerange first="299" last="305"/> </ref-volisspag> </ref-info> <ref-fulltext>19 Hasanovic, A., Ang, D., Moreira, A.L., Zakowski, M.F., Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 77 (2012), 299–305.</ref-fulltext> </reference> <reference id="20"> <ref-info> <ref-title> <ref-titletext>Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib20</itemid> <itemid idtype="SGR">84886833941</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>H.L.</ce:initials> <ce:indexed-name>Ho H.L.</ce:indexed-name> <ce:surname>Ho</ce:surname> </author> <author seq="2"> <ce:initials>F.P.</ce:initials> <ce:indexed-name>Chang F.P.</ce:indexed-name> <ce:surname>Chang</ce:surname> </author> <author seq="3"> <ce:initials>H.H.</ce:initials> <ce:indexed-name>Ma H.H.</ce:indexed-name> <ce:surname>Ma</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Respirology</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="18"/> <pagerange first="1261" last="1270"/> </ref-volisspag> </ref-info> <ref-fulltext>20 Ho, H.L., Chang, F.P., Ma, H.H., et al. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirology 18 (2013), 1261–1270.</ref-fulltext> </reference> <reference id="21"> <ref-info> <ref-title> <ref-titletext>Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib21</itemid> <itemid idtype="SGR">84864296896</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Hofman P.</ce:indexed-name> <ce:surname>Hofman</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Ilie M.</ce:indexed-name> <ce:surname>Ilie</ce:surname> </author> <author seq="3"> <ce:initials>V.</ce:initials> <ce:indexed-name>Hofman V.</ce:indexed-name> <ce:surname>Hofman</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Ann Oncol</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="23"/> <pagerange first="1738" last="1743"/> </ref-volisspag> </ref-info> <ref-fulltext>21 Hofman, P., Ilie, M., Hofman, V., et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 23 (2012), 1738–1743.</ref-fulltext> </reference> <reference id="22"> <ref-info> <ref-title> <ref-titletext>EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib22</itemid> <itemid idtype="SGR">84961329529</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Houang M.</ce:indexed-name> <ce:surname>Houang</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Sioson L.</ce:indexed-name> <ce:surname>Sioson</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Clarkson A.</ce:indexed-name> <ce:surname>Clarkson</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Pathology</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="46"/> <pagerange first="501" last="508"/> </ref-volisspag> </ref-info> <ref-fulltext>22 Houang, M., Sioson, L., Clarkson, A., et al. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology 46 (2014), 501–508.</ref-fulltext> </reference> <reference id="23"> <ref-info> <ref-title> <ref-titletext>Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib23</itemid> <itemid idtype="SGR">77957956767</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.I.</ce:initials> <ce:indexed-name>Ilie M.I.</ce:indexed-name> <ce:surname>Ilie</ce:surname> </author> <author seq="2"> <ce:initials>V.</ce:initials> <ce:indexed-name>Hofman V.</ce:indexed-name> <ce:surname>Hofman</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Bonnetaud C.</ce:indexed-name> <ce:surname>Bonnetaud</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Virchows Arch</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="457"/> <pagerange first="483" last="495"/> </ref-volisspag> </ref-info> <ref-fulltext>23 Ilie, M.I., Hofman, V., Bonnetaud, C., et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 457 (2010), 483–495.</ref-fulltext> </reference> <reference id="24"> <ref-info> <ref-title> <ref-titletext>Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib24</itemid> <itemid idtype="SGR">84874835176</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Jiang G.</ce:indexed-name> <ce:surname>Jiang</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Fan C.</ce:indexed-name> <ce:surname>Fan</ce:surname> </author> <author seq="3"> <ce:initials>X.</ce:initials> <ce:indexed-name>Zhang X.</ce:indexed-name> <ce:surname>Zhang</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>PLoS One</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="8"/> <pagerange first="e59183"/> </ref-volisspag> </ref-info> <ref-fulltext>24 Jiang, G., Fan, C., Zhang, X., et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS One, 8, 2013, e59183.</ref-fulltext> </reference> <reference id="25"> <ref-info> <ref-title> <ref-titletext>Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib25</itemid> <itemid idtype="SGR">77958198161</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Kato Y.</ce:indexed-name> <ce:surname>Kato</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>Peled N.</ce:indexed-name> <ce:surname>Peled</ce:surname> </author> <author seq="3"> <ce:initials>M.W.</ce:initials> <ce:indexed-name>Wynes M.W.</ce:indexed-name> <ce:surname>Wynes</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Thorac Oncol</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="5"/> <pagerange first="1551" last="1558"/> </ref-volisspag> </ref-info> <ref-fulltext>25 Kato, Y., Peled, N., Wynes, M.W., et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 5 (2010), 1551–1558.</ref-fulltext> </reference> <reference id="26"> <ref-info> <ref-title> <ref-titletext>Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib26</itemid> <itemid idtype="SGR">80052588962</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Kawahara A.</ce:indexed-name> <ce:surname>Kawahara</ce:surname> </author> <author seq="2"> <ce:initials>K.</ce:initials> <ce:indexed-name>Azuma K.</ce:indexed-name> <ce:surname>Azuma</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Sumi A.</ce:indexed-name> <ce:surname>Sumi</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Lung Cancer</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="74"/> <pagerange first="35" last="40"/> </ref-volisspag> </ref-info> <ref-fulltext>26 Kawahara, A., Azuma, K., Sumi, A., et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 74 (2011), 35–40.</ref-fulltext> </reference> <reference id="27"> <ref-info> <ref-title> <ref-titletext>Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib27</itemid> <itemid idtype="SGR">77953720122</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Kawahara A.</ce:indexed-name> <ce:surname>Kawahara</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Yamamoto C.</ce:indexed-name> <ce:surname>Yamamoto</ce:surname> </author> <author seq="3"> <ce:initials>K.</ce:initials> <ce:indexed-name>Nakashima K.</ce:indexed-name> <ce:surname>Nakashima</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Clin Cancer Res</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="16"/> <pagerange first="3163" last="3170"/> </ref-volisspag> </ref-info> <ref-fulltext>27 Kawahara, A., Yamamoto, C., Nakashima, K., et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16 (2010), 3163–3170.</ref-fulltext> </reference> <reference id="28"> <ref-info> <ref-title> <ref-titletext>Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib28</itemid> <itemid idtype="SGR">77954224784</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Kitamura A.</ce:indexed-name> <ce:surname>Kitamura</ce:surname> </author> <author seq="2"> <ce:initials>W.</ce:initials> <ce:indexed-name>Hosoda W.</ce:indexed-name> <ce:surname>Hosoda</ce:surname> </author> <author seq="3"> <ce:initials>E.</ce:initials> <ce:indexed-name>Sasaki E.</ce:indexed-name> <ce:surname>Sasaki</ce:surname> </author> <author seq="4"> <ce:initials>T.</ce:initials> <ce:indexed-name>Mitsudomi T.</ce:indexed-name> <ce:surname>Mitsudomi</ce:surname> </author> <author seq="5"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Yatabe Y.</ce:indexed-name> <ce:surname>Yatabe</ce:surname> </author> </ref-authors> <ref-sourcetitle>Clin Cancer Res</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="16"/> <pagerange first="3349" last="3355"/> </ref-volisspag> </ref-info> <ref-fulltext>28 Kitamura, A., Hosoda, W., Sasaki, E., Mitsudomi, T., Yatabe, Y., Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 16 (2010), 3349–3355.</ref-fulltext> </reference> <reference id="29"> <ref-info> <ref-title> <ref-titletext>The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib29</itemid> <itemid idtype="SGR">79957676308</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Kozu Y.</ce:indexed-name> <ce:surname>Kozu</ce:surname> </author> <author seq="2"> <ce:initials>K.</ce:initials> <ce:indexed-name>Tsuta K.</ce:indexed-name> <ce:surname>Tsuta</ce:surname> </author> <author seq="3"> <ce:initials>T.</ce:initials> <ce:indexed-name>Kohno T.</ce:indexed-name> <ce:surname>Kohno</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Lung Cancer</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="73"/> <pagerange first="45" last="50"/> </ref-volisspag> </ref-info> <ref-fulltext>29 Kozu, Y., Tsuta, K., Kohno, T., et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 73 (2011), 45–50.</ref-fulltext> </reference> <reference id="30"> <ref-info> <ref-title> <ref-titletext>Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib30</itemid> <itemid idtype="SGR">78751560428</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>H.</ce:initials> <ce:indexed-name>Nakamura H.</ce:indexed-name> <ce:surname>Nakamura</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Mochizuki A.</ce:indexed-name> <ce:surname>Mochizuki</ce:surname> </author> <author seq="3"> <ce:initials>T.</ce:initials> <ce:indexed-name>Shinmyo T.</ce:indexed-name> <ce:surname>Shinmyo</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Anticancer Res</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="30"/> <pagerange first="5233" last="5237"/> </ref-volisspag> </ref-info> <ref-fulltext>30 Nakamura, H., Mochizuki, A., Shinmyo, T., et al. Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. Anticancer Res 30 (2010), 5233–5237.</ref-fulltext> </reference> <reference id="31"> <ref-info> <ref-title> <ref-titletext>Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib31</itemid> <itemid idtype="SGR">84925534529</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Ping W.</ce:indexed-name> <ce:surname>Ping</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Xia C.</ce:indexed-name> <ce:surname>Xia</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Fu S.</ce:indexed-name> <ce:surname>Fu</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Tumour Biol</ref-sourcetitle> <ref-publicationyear first="2015"/> <ref-volisspag> <voliss volume="36"/> <pagerange first="693" last="700"/> </ref-volisspag> </ref-info> <ref-fulltext>31 Ping, W., Xia, C., Fu, S., et al. Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma. Tumour Biol 36 (2015), 693–700.</ref-fulltext> </reference> <reference id="32"> <ref-info> <ref-title> <ref-titletext>Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib32</itemid> <itemid idtype="SGR">84971624301</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Ragazzi M.</ce:indexed-name> <ce:surname>Ragazzi</ce:surname> </author> <author seq="2"> <ce:initials>I.</ce:initials> <ce:indexed-name>Tamagnini I.</ce:indexed-name> <ce:surname>Tamagnini</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Bisagni A.</ce:indexed-name> <ce:surname>Bisagni</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Pathol</ref-sourcetitle> <ref-publicationyear first="2016"/> <ref-volisspag> <voliss volume="69"/> <pagerange first="440" last="447"/> </ref-volisspag> </ref-info> <ref-fulltext>32 Ragazzi, M., Tamagnini, I., Bisagni, A., et al. Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. J Clin Pathol 69 (2016), 440–447.</ref-fulltext> </reference> <reference id="33"> <ref-info> <ref-title> <ref-titletext>Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib33</itemid> <itemid idtype="SGR">84894225202</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.N.</ce:initials> <ce:indexed-name>Seo A.N.</ce:indexed-name> <ce:surname>Seo</ce:surname> </author> <author seq="2"> <ce:initials>T.I.</ce:initials> <ce:indexed-name>Park T.I.</ce:indexed-name> <ce:surname>Park</ce:surname> </author> <author seq="3"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Jin Y.</ce:indexed-name> <ce:surname>Jin</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Lung Cancer</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="83"/> <pagerange first="316" last="323"/> </ref-volisspag> </ref-info> <ref-fulltext>33 Seo, A.N., Park, T.I., Jin, Y., et al. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer 83 (2014), 316–323.</ref-fulltext> </reference> <reference id="34"> <ref-info> <ref-title> <ref-titletext>Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib34</itemid> <itemid idtype="SGR">78650928556</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Simonetti S.</ce:indexed-name> <ce:surname>Simonetti</ce:surname> </author> <author seq="2"> <ce:initials>M.A.</ce:initials> <ce:indexed-name>Molina M.A.</ce:indexed-name> <ce:surname>Molina</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Queralt C.</ce:indexed-name> <ce:surname>Queralt</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Transl Med</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="8"/> <pagerange first="135"/> </ref-volisspag> </ref-info> <ref-fulltext>34 Simonetti, S., Molina, M.A., Queralt, C., et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med, 8, 2010, 135.</ref-fulltext> </reference> <reference id="35"> <ref-info> <ref-title> <ref-titletext>Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib35</itemid> <itemid idtype="SGR">84861338508</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.H.</ce:initials> <ce:indexed-name>Tsai T.H.</ce:indexed-name> <ce:surname>Tsai</ce:surname> </author> <author seq="2"> <ce:initials>S.G.</ce:initials> <ce:indexed-name>Wu S.G.</ce:indexed-name> <ce:surname>Wu</ce:surname> </author> <author seq="3"> <ce:initials>Y.L.</ce:initials> <ce:indexed-name>Chang Y.L.</ce:indexed-name> <ce:surname>Chang</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Thorac Oncol</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="993" last="1000"/> </ref-volisspag> </ref-info> <ref-fulltext>35 Tsai, T.H., Wu, S.G., Chang, Y.L., et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 7 (2012), 993–1000.</ref-fulltext> </reference> <reference id="36"> <ref-info> <ref-title> <ref-titletext>A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib36</itemid> <itemid idtype="SGR">84906248830</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>X.</ce:initials> <ce:indexed-name>Wang X.</ce:indexed-name> <ce:surname>Wang</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Wang G.</ce:indexed-name> <ce:surname>Wang</ce:surname> </author> <author seq="3"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Hao Y.</ce:indexed-name> <ce:surname>Hao</ce:surname> </author> <author seq="4"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Xu Y.</ce:indexed-name> <ce:surname>Xu</ce:surname> </author> <author seq="5"> <ce:initials>L.</ce:initials> <ce:indexed-name>Zhang L.</ce:indexed-name> <ce:surname>Zhang</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int J Clin Exp Pathol</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="4310" last="4316"/> </ref-volisspag> </ref-info> <ref-fulltext>36 Wang, X., Wang, G., Hao, Y., Xu, Y., Zhang, L., A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer. Int J Clin Exp Pathol 7 (2014), 4310–4316.</ref-fulltext> </reference> <reference id="37"> <ref-info> <ref-title> <ref-titletext>Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib37</itemid> <itemid idtype="SGR">79961212400</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.G.</ce:initials> <ce:indexed-name>Wu S.G.</ce:indexed-name> <ce:surname>Wu</ce:surname> </author> <author seq="2"> <ce:initials>Y.L.</ce:initials> <ce:indexed-name>Chang Y.L.</ce:indexed-name> <ce:surname>Chang</ce:surname> </author> <author seq="3"> <ce:initials>J.W.</ce:initials> <ce:indexed-name>Lin J.W.</ce:indexed-name> <ce:surname>Lin</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>PLoS One</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="6"/> <pagerange first="e23303"/> </ref-volisspag> </ref-info> <ref-fulltext>37 Wu, S.G., Chang, Y.L., Lin, J.W., et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One, 6, 2011, e23303.</ref-fulltext> </reference> <reference id="38"> <ref-info> <ref-title> <ref-titletext>Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib38</itemid> <itemid idtype="SGR">84873938814</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Xiong Y.</ce:indexed-name> <ce:surname>Xiong</ce:surname> </author> <author seq="2"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Bai Y.</ce:indexed-name> <ce:surname>Bai</ce:surname> </author> <author seq="3"> <ce:initials>N.</ce:initials> <ce:indexed-name>Leong N.</ce:indexed-name> <ce:surname>Leong</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Diagn Pathol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="8"/> <pagerange first="27"/> </ref-volisspag> </ref-info> <ref-fulltext>38 Xiong, Y., Bai, Y., Leong, N., et al. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol, 8, 2013, 27.</ref-fulltext> </reference> <reference id="39"> <ref-info> <ref-title> <ref-titletext>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib39</itemid> <itemid idtype="SGR">57849117384</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.A.</ce:initials> <ce:indexed-name>Eisenhauer E.A.</ce:indexed-name> <ce:surname>Eisenhauer</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Therasse P.</ce:indexed-name> <ce:surname>Therasse</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Bogaerts J.</ce:indexed-name> <ce:surname>Bogaerts</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Eur J Cancer</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="45"/> <pagerange first="228" last="247"/> </ref-volisspag> </ref-info> <ref-fulltext>39 Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.</ref-fulltext> </reference> <reference id="40"> <ref-info> <ref-title> <ref-titletext>Two-sided confidence intervals for the single proportion: comparison of seven methods</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib40</itemid> <itemid idtype="SGR">0032580320</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.G.</ce:initials> <ce:indexed-name>Newcombe R.G.</ce:indexed-name> <ce:surname>Newcombe</ce:surname> </author> </ref-authors> <ref-sourcetitle>Stat Med</ref-sourcetitle> <ref-publicationyear first="1998"/> <ref-volisspag> <voliss volume="17"/> <pagerange first="857" last="872"/> </ref-volisspag> </ref-info> <ref-fulltext>40 Newcombe, R.G., Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17 (1998), 857–872.</ref-fulltext> </reference> <reference id="41"> <ref-info> <ref-title> <ref-titletext>Probable inference, the law of succession, and statistical inference</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib41</itemid> <itemid idtype="SGR">84946650481</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.B.</ce:initials> <ce:indexed-name>Wilson E.B.</ce:indexed-name> <ce:surname>Wilson</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Am Stat Assoc</ref-sourcetitle> <ref-publicationyear first="1927"/> <ref-volisspag> <voliss volume="22"/> <pagerange first="209" last="212"/> </ref-volisspag> </ref-info> <ref-fulltext>41 Wilson, E.B., Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22 (1927), 209–212.</ref-fulltext> </reference> <reference id="42"> <ref-info> <ref-title> <ref-titletext>Identification of EGFR mutations by Immunohistochemistry with EGFR mutation-specific antibodies in biopsy and resection specimens from pulmonary adenocarcinoma</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib42</itemid> <itemid idtype="SGR">84946709934</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.H.</ce:initials> <ce:indexed-name>Kim C.H.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="2"> <ce:initials>S.H.</ce:initials> <ce:indexed-name>Kim S.H.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="3"> <ce:initials>S.Y.</ce:initials> <ce:indexed-name>Park S.Y.</ce:indexed-name> <ce:surname>Park</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Yoo J.</ce:indexed-name> <ce:surname>Yoo</ce:surname> </author> <author seq="5"> <ce:initials>S.K.</ce:initials> <ce:indexed-name>Kim S.K.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="6"> <ce:initials>H.K.</ce:initials> <ce:indexed-name>Kim H.K.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> </ref-authors> <ref-sourcetitle>Cancer Res Treat</ref-sourcetitle> <ref-publicationyear first="2015"/> <ref-volisspag> <voliss volume="47"/> <pagerange first="653" last="660"/> </ref-volisspag> </ref-info> <ref-fulltext>42 Kim, C.H., Kim, S.H., Park, S.Y., Yoo, J., Kim, S.K., Kim, H.K., Identification of EGFR mutations by Immunohistochemistry with EGFR mutation-specific antibodies in biopsy and resection specimens from pulmonary adenocarcinoma. Cancer Res Treat 47 (2015), 653–660.</ref-fulltext> </reference> <reference id="43"> <ref-info> <ref-title> <ref-titletext>Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib43</itemid> <itemid idtype="SGR">84655163448</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>K.</ce:initials> <ce:indexed-name>Azuma K.</ce:indexed-name> <ce:surname>Azuma</ce:surname> </author> <author seq="2"> <ce:initials>I.</ce:initials> <ce:indexed-name>Okamoto I.</ce:indexed-name> <ce:surname>Okamoto</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Kawahara A.</ce:indexed-name> <ce:surname>Kawahara</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Thorac Oncol</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="122" last="127"/> </ref-volisspag> </ref-info> <ref-fulltext>43 Azuma, K., Okamoto, I., Kawahara, A., et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 7 (2012), 122–127.</ref-fulltext> </reference> <reference id="44"> <ref-info> <ref-title> <ref-titletext>The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib44</itemid> <itemid idtype="SGR">84901617176</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Zhao J.</ce:indexed-name> <ce:surname>Zhao</ce:surname> </author> <author seq="2"> <ce:initials>X.</ce:initials> <ce:indexed-name>Wang X.</ce:indexed-name> <ce:surname>Wang</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Xue L.</ce:indexed-name> <ce:surname>Xue</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Cancer Res Clin Oncol</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="140"/> <pagerange first="849" last="857"/> </ref-volisspag> </ref-info> <ref-fulltext>44 Zhao, J., Wang, X., Xue, L., et al. The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer. J Cancer Res Clin Oncol 140 (2014), 849–857.</ref-fulltext> </reference> <reference id="45"> <ref-info> <ref-title> <ref-titletext>Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="FRAGMENTID">bib45</itemid> <itemid idtype="SGR">84880312534</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>V.M.</ce:initials> <ce:indexed-name>Singh V.M.</ce:indexed-name> <ce:surname>Singh</ce:surname> </author> <author seq="2"> <ce:initials>R.C.</ce:initials> <ce:indexed-name>Salunga R.C.</ce:indexed-name> <ce:surname>Salunga</ce:surname> </author> <author seq="3"> <ce:initials>V.J.</ce:initials> <ce:indexed-name>Huang V.J.</ce:indexed-name> <ce:surname>Huang</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Ann Diagn Pathol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="17"/> <pagerange first="322" last="326"/> </ref-volisspag> </ref-info> <ref-fulltext>45 Singh, V.M., Salunga, R.C., Huang, V.J., et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol 17 (2013), 322–326.</ref-fulltext> </reference> </bibliography></tail></bibrecord></item></abstracts-retrieval-response>